Folinic Acid Concerns
Folinic Acid Concerns
Folinic acid is being discussed as an autism intervention, but the trial history, publication context, and biochemical mechanism require closer scrutiny before it is framed as a reliable treatment pathway.
The concern is not whether folinic acid may produce effects in some children. The concern is whether the evidence is being interpreted with sufficient precision given the trial history, unresolved compliance issues, and the specific biochemical pathway being engaged.
Folinic acid is not interchangeable with other folate forms. It is a formyl folate, not a methyl folate, and formyl forms of folate are used in cell turnover in biology rather than methylation.
Folinic acid (5-formyl-THF) is converted by MTHFS into 5,10-methenyl-THF and subsequently 5,10-methylene-THF, increasing availability of the reduced folate required for thymidylate synthase activity.
Under Michaelis–Menten kinetics, increasing substrate availability can drive pathway flux independent of upstream signaling.
In oncology, this mechanism is used to increase formation of the thymidylate synthase ternary complex (TS•FdUMP•5,10-methylene-THF), which inhibits thymidylate synthase and reduces DNA synthesis and cell turnover.
In non-chemotherapy contexts, this inhibitory step is absent. Increasing substrate availability without pathway blockade may shift nucleotide availability and replication dynamics. In actively developing tissues, this raises a mechanistic concern that chronic exposure could alter replication or repair processes. Long-term pediatric safety data remain limited.
Published After Termination
The study later published as Frye et al. 2018 is associated with NCT01602016, listed as terminated for investigator non-compliance and placed on a full FDA clinical hold.
Issues Not Resolved Before Publication
This page states that UAMS confirmed the compliance issues were not resolved prior to publication, raising questions about how a full trial report was released without that context.
Patented Test Used in Study
Two coauthors are identified as inventors on the folate receptor autoantibody test used in the study, introducing a conflict-of-interest concern alongside later promotion of folinic acid as a treatment.
Before folinic acid is positioned as a meaningful autism intervention, the study integrity, unresolved trial status, mechanistic rationale, and conflict-of-interest context require more precise evaluation.